Wereport a 67-year-old male patient with a knownhistory ofsarcoidosis in remission who had recurrent sarcoidosis following a five-month administration of interferon alpha (IFN-oc) for chronic hepatitis C. He developed bilateral swelling of the parotid glands and bilateral diffuse reticulonodular pulmonary parenchymal opacities on chest roentgenograms. Serumangiotensin converting enzyme (ACE) levels and soluble IL-2 receptor levels were high and a transbronchial lung biopsy revealed noncaseating granulomas. The abnormalities on both laboratory data and chest roentgenograms were resolved after administration of oral prednisolone.
Introduction
IFN may induce antiviral, antigrowth and immunomodulatory effects (1) . IFN-a is knownto suppress viral replication and to restore elevated serum aminotransferase levels, leading to an improvement in the histological changes in the liver in patients with chronic hepatitis C (2, 3) . However, IFN-a is also known to induce various autoimmunedisorders, such as interstitial pneumonia, systemic lupus erythematosus, autoimmune hemolytic anemia, hypothyroidism and immune thrombocytopenia (4) (5) (6) (7) (8) (9) . Here, we describe a patient with symptoms, and radiographic and pathologic changes indicative of recurrent pulmonary sarcoidosis following IFN-a therapy for chronic active hepatitis C.
Case Report
A 67-year-old nonsmokingmale with shortness of breath and chronic hepatitis was diagnosed as having sarcoidosis in December 1978, because partially resected right parotid gland and transbronchial lung biopsy specimens showed noncaseating granulomas, and there was a high serum ACElevel. Further, bilateral hilar lymphadenopathy with bilateral parenchymal reticulonodular opacities on chest roentgenograms were present.
He was treated at that time with oral prednisolone for swelling of bilateral parotid glands and shortness of breath. Over the subsequent month, the abnormal findings on chest roentgenograms and the high serum ACElevel were gradually resolved, the swelling of the parotid glands and shortness of breath disappeared, and oral prednisolone therapy was tapered off. However, slight liver damage continued. In June 1993, 15 years after the diagnosis of sarcoidosis, the presence of antibody to the hepatitis C virus was detected. A transcutaneous liver biopsy disclosed destruction of the limited plate, portal mononuclear infiltration and piece-meal necrosis, which were compatible with the findings of chronic active hepatitis. IFN-a therapy was started on December 1, 1993 for chronic active hepatitis C. Five months after the IFN-a therapy was begun, the patient complained of swelling of both parotid glands and shortness of breath, and the chest roentgenograms revealed diffuse reticulonodular pulmonary parenchymal opacities (Fig.  1) . In May 1994, when he had taken atotal amountof60 million units ofIFN-a, high-resolution computedtomographicscans of lungs confirmed diffuse small nodular lesions (Fig. 2) . He had not newly taken any medicine. A 67Ga citrate scan showed increased radiogallium uptake in both lung parenchyma, the mediastinum or both hilar lymph nodes and both parotid glands (Fig. 3) . Transbronchial lung biopsy specimens revealed noncaseating granulomas with lymphocyte infiltration consistent with sarcoidosis ( Fig. 4) . A bronchoalveolar lavage was also performed, and all stains and cultures were negative for fungal, acid-fast bacilli and other bacterial infections. Laboratory studies on admission revealed a hematocrit of 41%and a white blood cell count of 4,300/jjI, with normal swelling of the parotid glands; 3) ahigh serum ACE level; 4) the presence of noncaseating granulomas in the right parotid gland and lung parenchyma; 5) all of the above findings were observed in both episodes (1978 and 1993) . IFN was originally described as a protein capable of inducing antiviral activity in cells (1) . Subsequently, it was found that manydifferent interferon types exist and that they exert various effects on the immunesystem, including modulation of immunoglobulin production as well as stimulation of T cell cytotoxicity, macrophage functions, and natural killer cell activity. Consequently, the use of interferons in the treatment of chronic hepatitis C is increasing (2, 3) . Interstitial pneumonia may possibly be induced by IFN-a administration. The incidence of IFN-a-induced interstitial pneumonia is particularly high when IFN-a is used in combination with some type of herbal medicine (Sho-Saiko-To) (4). However, the present patient did not take any other drugs and no herbal medicines. Incidences of IFN-a-induced interstitial pneumoniaafter two monthsand after a total dose of over 100 x 104 1.U. are noted to be higher. Although the pathogenesis of this disease remains unclear, presence of some cytokines from mononuclear cells which are activated by IFN-a might play a role in producing interstitial pneumonia. 53-87% (18, 19) . Although the effectiveness of IFN therapy has been substantiated in some malignancies, chronic hepatitis C, and some infectious diseases (20), we emphasize attention to the possibility of recurrence of sarcoidosis in patients receiving IFN therapy who have had a history of sarcoidosis. Even ifsarcoidosis is notpresent when IFN therapy is initiated, the patient's past history should be checked carefully for the occurrence of sarcoidosis. In summary, wereported a rare case in whom sarcoidosis recurred following IFN-a therapy for chronic hepatitis C. This case suggests the possibility that IFN-a may be involved with, or maytrigger the sarcoid reaction.
